Polygenic score

on polygenic risk score with increasing age. + The left panel shows how risk (the standardized PRS on the x-axis) can separate 'cases' (i.e., individuals with a certain disease, (red)) from the 'controls' (individuals without the disease…

Uses your system voice; voice and rate in settings.

Snapshot

≈ 8 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

on polygenic risk score with increasing age. + The left panel shows how risk (the standardized PRS on the x-axis) can separate 'cases' (i.e., individuals with a certain disease, (red)) from the 'controls' (individuals without the disease, (blue)). The y-axis (vertical axis) indicates how many in each group are assigned a certain score. + At the right panel, the same population is divided into three groups according to their predicted risk, i.e., their assigned score, as high (red), middle (gray), or low (blue).

The y-axis shows the observed risk amounts, where the x-axis shows the groups separating in risk as they age corresponding with the predicted risk scores. In genetics, a polygenic score (PGS) is a number that summarizes the estimated effect of many genetic variants on an individual's phenotype.

The PGS is also called the polygenic index (PGI) or genome-wide score; in the context of disease risk, it is called a polygenic risk score (PRS or PR score ) or genetic risk score. The score reflects an individual's estimated genetic predisposition for a given trait and can be used as a predictor for that trait.

It gives an estimate of how likely an individual is to have a given trait based only on genetics, without taking environmental factors into account; and it is typically calculated as a weighted sum of trait-associated alleles.…

on polygenic risk score with increasing age. + The left panel shows how risk (the standardized PRS on the x-axis) can separate 'cases' (i.e., individuals with a certain disease, (red)) from the 'controls' (individuals without the disease, (blue)). The y-axis (vertical axis) indicates how many in each group are assigned a certain score. + At the right panel, the same population is divided into three groups according to their predicted risk, i.e., their assigned score, as high (red), middle (gray), or low (blue).

The y-axis shows the observed risk amounts, where the x-axis shows the groups separating in risk as they age corresponding with the predicted risk scores. In genetics, a polygenic score (PGS) is a number that summarizes the estimated effect of many genetic variants on an individual's phenotype.

The PGS is also called the polygenic index (PGI) or genome-wide score; in the context of disease risk, it is called a polygenic risk score (PRS or PR score ) or genetic risk score. The score reflects an individual's estimated genetic predisposition for a given trait and can be used as a predictor for that trait.

It gives an estimate of how likely an individual is to have a given trait based only on genetics, without taking environmental factors into account; and it is typically calculated as a weighted sum of trait-associated alleles. Recent progress in genetics has developed polygenic predictors of complex human traits, including risk for many important complex diseases that are typically affected by many genetic variants, each of which confers a small effect on overall risk.

In a polygenic risk predictor, the lifetime (or age-range) risk for the disease is a numerical function captured by the score which depends on the states of thousands of individual genetic variants (i.e., single-nucleotide polymorphisms, or SNPs). Polygenic scores are widely used in animal breeding and plant breeding due to their efficacy in improving livestock breeding and crops.

In humans, polygenic scores are typically generated from data of genome-wide association study (GWAS). They are an active area of research spanning topics such as learning algorithms for genomic prediction; new predictor training; validation testing of predictors; and clinical application of PRS.

In 2018, the American Heart Association named polygenic risk scores as one of the major breakthroughs in research in heart disease and stroke. \hat{S} = \sum_{j=1}^{m} X_{j} \hat{\beta}_{j} This idea can be generalized to the study of any trait and is an example of the more general mathematical term regression analysis.

Key considerations

Methods for generating polygenic scores in humans are an active area of research. Two key considerations in developing polygenic scores are which SNPs and the number of SNPs to include. The simplest method—the so-called "pruning and thresholding" method—sets weights equal to the coefficient estimates from a regression of the trait on each genetic variant.

The included SNPs may be selected using an algorithm that attempts to ensure that each marker is approximately independent. The independence of each SNP is important for the score's predictive accuracy.

SNPs that are physically close to each other are more likely to be in linkage disequilibrium, meaning they typically are inherited together and therefore do not provide independent predictive power. The removal of these SNPs is called "pruning". The "thresholding" refers to using only SNPs that meet a specific p-value threshold.

Penalized regression can also be used to construct polygenic scores. From prior information, penalized regression assigns probabilities based on: 1) how many genetic variants are expected to affect a trait and 2) the distribution of their effect sizes. These methods, in effect, "penalize" the large coefficients in a regression model and shrink them conservatively.

One popular tool for this approach is "PRS-CS". Another is to use Bayesian methods, first proposed in 2001, that directly incorporate genetic features of a given trait and genomic features like linkage disequilibrium. One Bayesian method uses "linkage disequilibrium prediction" or LDpred.

More approaches for developing polygenic risk scores continue to be described. For example, by incorporating effect sizes from populations of different ancestral backgrounds, the predictive ability of scores can be improved. Incorporating knowledge of the functional roles of specific genomic chunks can improve the utility of scores.

Studies have examined the performances of these methods on standardized dataset.

Clinical utility and current usage

A landmark study examining the role of polygenic risk scores in cardiovascular disease invigorated interest the clinical potential of polygenic scores. This study demonstrated that an individual with the highest polygenic risk score (top 1%) had a lifetime cardiovascular risk >10% which was comparable to those with rare genetic variants.

This comparison is important because clinical practice can be influenced by knowing which individuals have this rare genetic cause of cardiovascular disease. Since this study, polygenic risk scores have shown promise for disease prediction across other traits.

Polygenic risk scores have been studied heavily in obesity, coronary artery disease, diabetes, breast cancer, prostate cancer, Alzheimer's disease and psychiatric diseases. As of January 2021 providing PRS directly to individuals was undergoing research trials in health systems around the world, but is not yet offered as standard of care.

Most use is therefore through consumer genetic testing, where a number of private companies report PRS for a number of diseases and traits. Consumers download their genotype (genetic variant) data and upload them into online PRS calculators, e.g. Scripps Health, Impute.me or Color Genomics.

The most frequently reported motivation for individuals to seek out PRS reports is general curiosity (98.2%), and the reactions are generally mixed with common misinterpretations. It is speculated that personal use of PRS could contribute to treatment choices, but that more data is needed.

As of 2020 a more typical use was that clinicians face individuals with commercially derived disease-specific PRS in the expectation that the clinician will interpret them, something that may create extra burdens for the clinical care system.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1369696907 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

11 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.